Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 221.4 SEK 4.04% Market Closed
Market Cap: 30B SEK
Have any thoughts about
Vitrolife AB?
Write Note

Vitrolife AB
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vitrolife AB
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Vitrolife AB
STO:VITR
Total Liabilities & Equity
kr16.9B
CAGR 3-Years
40%
CAGR 5-Years
52%
CAGR 10-Years
41%
Biogaia AB
STO:BIOG B
Total Liabilities & Equity
kr2.3B
CAGR 3-Years
7%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Total Liabilities & Equity
kr778.7m
CAGR 3-Years
31%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Probi AB
STO:PROB
Total Liabilities & Equity
kr1.6B
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
26%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Total Liabilities & Equity
kr72.2B
CAGR 3-Years
16%
CAGR 5-Years
17%
CAGR 10-Years
27%
BioArctic AB
STO:BIOA B
Total Liabilities & Equity
kr1.2B
CAGR 3-Years
4%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
No Stocks Found

Vitrolife AB
Glance View

Market Cap
30B SEK
Industry
Biotechnology

Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 427 full-time employees. The company went IPO on 2001-06-26. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. The company also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The firm is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.

VITR Intrinsic Value
139.61 SEK
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Vitrolife AB's Total Liabilities & Equity?
Total Liabilities & Equity
16.9B SEK

Based on the financial report for Sep 30, 2024, Vitrolife AB's Total Liabilities & Equity amounts to 16.9B SEK.

What is Vitrolife AB's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
41%

Over the last year, the Total Liabilities & Equity growth was -20%. The average annual Total Liabilities & Equity growth rates for Vitrolife AB have been 40% over the past three years , 52% over the past five years , and 41% over the past ten years .

Back to Top